<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00043381</url>
  </required_header>
  <id_info>
    <org_study_id>D-0007</org_study_id>
    <nct_id>NCT00043381</nct_id>
    <nct_alias>NCT00022061</nct_alias>
  </id_info>
  <brief_title>Decitabine Versus Supportive Care in Adults With Advanced-stage MDS</brief_title>
  <official_title>A Randomized, Open-label, Phase III Trial of Decitabine (5-aza-2'Deoxycytidine) Versus Supportive Care in Adults With Advanced-stage Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astex Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astex Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      To compare the safety and efficacy profiles of decitabine to those of supportive care in&#xD;
      adults with advanced-stage myelodysplastic syndrome (MDS)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This experimental (investigational) study is intended to answer the question of whether&#xD;
      decitabine is any better than supportive care alone in delaying progression (worsening) of&#xD;
      the disease, prolonging survival or improving the overall quality of life for MDS patients&#xD;
      who are not candidates for bone marrow transplant (BMT).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <completion_date type="Actual">April 2003</completion_date>
  <primary_completion_date type="Actual">November 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>160</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>decitabine (5-aza-2'deoxycytidine)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
          -  MDS (de novo or secondary) fitting any of the recognized French-American-British, FAB,&#xD;
             classifications or chronic myelomonocytic leukemia (CMML) with WBC &lt; 12,000/mm3, AND&#xD;
             International Prognostic Scoring System (IPSS) &gt;/= 0.5 as determined by CBC, bone&#xD;
             marrow assessment and bone marrow cytogenetics within 30 days of randomization&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  Female patients of child-bearing potential must have a negative serum hCG within 24&#xD;
             hours prior to randomization, must practice a medically approved method of birth&#xD;
             control for the past 30 days, and agree to continue this practice for the trial&#xD;
             duration and must not be breast-feeding&#xD;
&#xD;
          -  ECOG or WHO performance status of 0-2&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Normal renal and hepatic function (creatinine &lt;/= 2 mg/dL, bilirubin &lt;/= 1.5 mg/dL,&#xD;
             SGPT &lt;/= 2 times the upper limit of normal range)&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          -  Acute Myeloid Leukemia (AML) (&gt;/=30% bone marrow blasts) or other progressive&#xD;
             malignant disease&#xD;
&#xD;
          -  Patients must have recovered from the toxic effects of prior therapy and must be off&#xD;
             all chemotherapy for a minimum of 4 weeks prior to study entry to the protocol (a&#xD;
             minimum of six weeks for prior nitrosoureas and bone marrow transplantation)&#xD;
&#xD;
          -  Ongoing treatment with androgenic hormones, danazol, colony-stimulating factors, or&#xD;
             other agents used to treat MDS within 7 days of study initiation.&#xD;
&#xD;
          -  Administration of any investigational agent within the 30 days preceding study&#xD;
             initiation.&#xD;
&#xD;
          -  Uncontrolled cardiac disease or congestive heart failure&#xD;
&#xD;
          -  Uncontrolled restrictive or obstructive pulmonary disease&#xD;
&#xD;
          -  Active viral or bacterial infection&#xD;
&#xD;
          -  Superimposed autoimmune hemolytic anemia or thrombocytopenia&#xD;
&#xD;
          -  Known positive serology for HIV&#xD;
&#xD;
          -  Mental illness or other condition preventing full cooperation with the treatment and&#xD;
             monitoring requirements of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alta Bates Comprehensive Cancer Center</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda Univ. Cancer Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. California San Francisco Medical School</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainsville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James A. Haley Veteran's Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Medical Center Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Univ. School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Memphis Cancer Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SW Regional Cancer Center (dba Central Texas Oncology Associates)</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>August 8, 2002</study_first_submitted>
  <study_first_submitted_qc>August 9, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2002</study_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <name_title>David S. Smith, Vice President-Regulatory and Quality Assurance</name_title>
    <organization>SuperGen, Inc.</organization>
  </responsible_party>
  <keyword>myelodysplastic syndrome</keyword>
  <keyword>MDS</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>CMML</keyword>
  <keyword>decitabine</keyword>
  <keyword>5-aza-2'deoxycytidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

